Maricann Group Inc. Announces $70 Million Bought Deal Equity Financing
BURLINGTON, ONTARIO–(Marketwired – Jan. 29, 2018) –
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) (“Maricann” or the “Company”), is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as joint bookrunner and co-lead underwriter with Canaccord Genuity Corp. (“Canaccord), and along with a syndicate of underwriters including GMP Securities L.P., Industrial Alliance Securities Inc. and Clarus Securities Inc. (together with Eight Capital and Canaccord, the “Underwriters”), 17,500,000 units of the Company (the “Units”), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $4.00 (the “Issue Price”) for gross proceeds of $70,000,000 (the “Offering”).
The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional $10,500,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $80,500,000.
Each Unit will be comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $4.15, for a period of 36 months following the closing of the Offering.
The Company intends to use the net proceeds of the Offering for acquisitions, capital expenditures and for working capital and general corporate purposes.
The closing date of the Offering is scheduled to be on or about February 23, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth. For more information about Maricann, please visit our website at www.maricann.com.
